Global Scleritis Market, By Type (Anterior Scleritis, Nodular Anterior Scleritis, Necrotizing Anterior Scleritis, Posterior Scleritis, Others), Diagnosis (Physical Examination, Laboratory Evaluations, Others), Treatment (Medication, Surgery, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Scleritis Market
Global scleritis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.70% in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
Moreover, technological advancement in treatment and diagnosis and rising incidence of eye diseases also boost up the market growth. Continuous rising prevalence of lupus, inflammatory bowel disease (IBD) and arthritis also boost up the market growth. But, adverse effect related to the treatment, may hamper the global scleritis market.
Scleritis is a severe ocular inflammatory condition affecting the sclera, the outer covering of the eye. Scleritis may occur in both the eyes and causes severe pain and inflammation. Scleritis can be idiopathic or caused by non-infectious or infectious conditions. Moreover, it is associated with the autoimmune disorders, malignancy, medication side effects or surgically induces side effects. Scleritis can be occurs due to the bacteria, fungi, viruses and parasites, which is reported to occurs in 4% to 10% of all cases. 50% of patients with scleritis will have an autoimmune condition, sometimes undiagnosed at the time of presentation.
It is estimated that Scleritis affecting 10,500 U.S. populations per year or an estimation of four to six cases per 100,000 persons. It majorly affects patients with middle age (45 to 60 years) and more commonly affects the female population with a predominance rate of 60 to 75%. Although, limited information is known about incidence of children besides case reports.
This scleritis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Scleritis Market Scope and Market Size
The scleritis market is segmented on the basis of type, diagnosis, treatment, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the scleritis market is segmented into anterior scleritis, nodular anterior scleritis, necrotizing anterior scleritis, posterior scleritis and others.
- On the basis of diagnosis, the scleritis market is segmented into physical examination, laboratory evaluations and others. Laboratory Evaluations further segmented into ultrasonography, complete blood count and sclera biopsy.
- On the basis of treatment, the scleritis market is segmented into medication, surgery and others. Medication segment further divided into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid pills, oral glucocorticoids, immunosuppressive drugs, antibiotics, antifungal medications and others.
- On the basis of end-users, the scleritis market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the scleritis market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Scleritis Market Country Level Analysis
Scleritis market is analysed and market size information is provided by country, type, diagnosis, treatment, end-users and distribution channel as referenced above.
The countries covered in the scleritis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment. Europe accounts the second largest market share due to increased genetic disorders and presence of refined medical facilities. Asia-Pacific is expected to account for the largest market share over coming years for the scleritis market due to constant rise in the incidence of autoimmune diseases coupled with increased demand for cost-efficient therapeutics.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Scleritis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Scleritis Market Share Analysis
Scleritis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to scleritis market.
The major players covered in the scleritis market are Mylan N.V., Zydus Pharmaceutical USA, Hikma Pharmaceutical PLC, Amgen Inc., Celltrion Inc., Pfizer Inc., Samsung Bioepis Co. Ltd., Genentech Inc., Baxter, Cipla, Novartis AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Fresenius Kabi USA, Accord Healthcare, West-Ward Pharms Int., Horizon Pharmaceutical, Sun Pharmaceutical Industries Ltd., Bayer AG, Alvogen., Perrigo Pharmaceutical Plc., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.